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Abstract
Guidelines recommend routine screening for colorectal cancer (CRC) in asymptomatic
adults starting at age 50. The most extensively used noninvasive test for CRC screening is
the fecal immunochemical test (FIT), which has an overall sensitivity for CRC of approxi-
mately 61.0%-91.0%, which drops to 27.0%-67.0% for advanced adenomas. These figures
contain a high false-positive rate and a low positive predictive value. This work aimed to
develop a new, noninvasive CRC screening tool based on fecal bacterial markers capable
of decreasing FIT false-positive rates in a FIT-positive population. We defined a fecal bacte-
rial signature (RAID-CRC Screen) in a proof-of-concept with 172 FIT-positive individuals
and validated the obtained results on an external cohort of 327 FIT-positive subjects. All
study participants had joined the national CRC screening program. In the clinical validation
of RAID-CRC Screen, a sensitivity of 83.9% and a specificity of 16.3% were obtained for the
detection of advanced neoplasm lesions (advanced adenomas and/or CRC). FIT 20 μg/g
produced 184 false-positive results. Using RAID-CRC Screen, this value was reduced to
154, thus reducing the false-positive rate by 16.3%. The RAID-CRC Screen test could be
implemented in CRC screening programs to allow a significant reduction in the number of
colonoscopies performed unnecessarily for FIT-positive participants of CRC screening
programs.
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer death worldwide, accounting
for more than 880,000 deaths in 2018 [1]. The highest incidence rates are found in the most
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developed countries (i.e., Australia, New Zealand, and countries in Europe and North Amer-
ica), while the lowest rates are found in the poorest countries (i.e., those in Africa and South-
central Asia). These geographic differences could be associated with Western diets and other
environmental aspects. Low socioeconomic status is also related to a higher risk for developing
CRC [2].
CRC mortality rates have declined progressively in many Western countries as govern-
ments have begun focusing their efforts at different prevention levels. Primary prevention
aims to decrease the risk of developing colorectal neoplasms by following a healthy diet and
lifestyle and chemoprevention [3]. CRC screening is a secondary prevention strategy for
reducing incidence and mortality by detecting and removing precursor lesions such as colo-
rectal adenomas [4]. A tertiary prevention strategy is CRC surveillance, which seeks to mini-
mize the impact of previously established colorectal neoplasms on the prognosis of the patient
[5].
CRC is a good candidate for disease screening, as it constitutes a significant health issue, its
natural history has been widely studied, diagnostic methods for its early detection are available
and its treatment is more effective when it is diagnosed early [6]. Moreover, screening pro-
grams for CRC have been demonstrated to be more cost-effective than other screening pro-
grams, such as those for breast and cervix cancers [7]. Improvement in screening quality and
adherence, however, is pivotal for further reducing the prevalence of CRC-associated death.
The most extensively used CRC screening strategies are based on endoscopic examinations
(i.e., colonoscopy and flexible sigmoidoscopy) and fecal tests (i.e., the guaiac-based fecal occult
blood test and fecal immunochemical test (FIT)). Colonoscopy is currently used as a CRC
screening method in countries such as Germany and Poland. Although its sensitivity and spec-
ificity for advanced neoplasia (AN; i.e., advanced adenoma (AA) and/or CRC) approaches
100% in experienced hands [8], it also has some limitations: it requires exhaustive bowel
cleansing and is time-consuming, painful, and expensive [9]. To overcome these limitations,
there is an increasing interest in the use of a two-step screening strategy by first using noninva-
sive screening and then after a positive result, performing the colonoscopy. The most com-
monly used noninvasive method is FIT, which specifically detects human hemoglobin in feces.
The quantitative nature of FIT allows the selection of an optimal cut-off concentration for the
desired target population.
Different screening programs have been implemented in regions of Spain for those aged
50-69 years. Most of these programs first use FIT (cut-off at 20 μg of hemoglobin/g of feces),
followed by a colonoscopy when a positive FIT result is obtained. In the Catalonia region, in
2013, 47.8% of the invited population agreed to participate in the CRC screening program, of
which 5.4% tested positive [10].
Data from 19 studies in which FIT performance in CRC screening was assessed showed
that the overall sensitivity and specificity for CRC were 79.0% and 94.0%, respectively [11].
Importantly, CRC screening strategies need to show high performance in detecting not only
CRC but also precancerous lesions. In this setting, FIT sensitivity for AAs has been shown to
be 28.0%, while its positive predictive value (PPV) has been shown to be 13.3%, which results
in a high false-positive rate for AN [12]. False-positive results lead to patient concerns and
unnecessary colonoscopies, with associated potential risks and costs. Therefore, in order to
reduce false-positive results, it is necessary to develop new noninvasive tools for CRC screen-
ing with higher specificity.
In recent years, growing attention has been given to the role of microbiota in carcinogene-
sis. Microorganisms are thought to be involved in up to 20.0% of cancers [13], specifically
colorectal cancer [14]. The intestinal mucosa is constantly exposed to the gut microbiota and
its derived metabolites, which have been observed to stimulate the immune response with the
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potential to cause inflammation [15]. Several research groups have sequenced the 16S rRNA
genes of bacteria from colonic mucosa or feces and reported that patients with CRC show
colorectal dysbiosis [16–19]. Some of the identified species are suspected to be involved in
colorectal tumorigenesis. These species include Gemella morbillorum (GMLL), Peptostrepto-
coccus stomatis (PTST), and Bacteroides fragilis (BCTF). All these data suggest that the fecal
gut microbiota is a potential alternative noninvasive tool for CRC screening. From these stud-
ies, we designed quantitative polymerase chain reaction (qPCR) systems that specifically target
those bacterial markers. Moreover, we have also studied other bacterial indicators retrieved
from other studies and previously developed by our group (i.e., B10, best BLAST match Faeca-
libacterium prausnitzii (FPRA); B46, best BLAST match Subdoligranulum variabile; and B48,
best BLAST match Ruminococcus sp., Roseburia sp., and Coprococcus sp.) [20,21].
In this work, we developed a new, noninvasive tool for CRC screening (i.e., RAID-CRC
Screen) based on a fecal bacterial signature that complements FIT and increases its specificity
and PPV for AN detection among FIT-positive participants. Proof-of-concept and clinical vali-
dation of the designed tool in two independent cohorts of an organized, population-based
CRC screening program are reported.
Methods
Study population
Participants of the Catalan CRC screening program were invited to participate in the study.
The inclusion criteria were as follows: (1) asymptomatic subjects; (2) subjects aged 50–69 years
(both included); and (3) subjects with a positive FIT result (cut-off at 20 μg of hemoglobin/g of
feces). The exclusion criteria were as follows: (1) subjects who had received antibiotics the
month prior to inclusion; (2) subjects who had received chemotherapy and/or radiotherapy
the last 6 months prior to inclusion; (3) subjects with severe comorbidity that, in the opinion
of the investigator, should preclude participation in the study; and (4) subjects who were preg-
nant at the time of inclusion.
In the proof-of-concept study, a cohort consisting of 189 consecutive FIT-positive partici-
pants in the Catalan CRC screening program was recruited (Table 1). The recruiting centers
were the Hospital Universitari Dr. Josep Trueta-IAS (Girona, Spain), the Hospital Universitari
de Bellvitge (L’Hospitalet de Llobregat, Spain), and the Consorci Hospitalari de Vic (Vic,
Spain). The study protocol (clinical investigation code: RAID-CRC 20202015) was approved
by the Clinical Research Ethics Committee of the three participating centers. Written informed
consent was obtained from all participants. From 189 recruited subjects, 17 had to be excluded
because of poor sample condition. Finally, 172 samples from asymptomatic subjects were used
in the proof-of-concept study.
Table 1. Characteristics of patients included in the proof-of-concept (RAID-CRC 20202015) and clinical validation (GG-RAIDCRC-1002) studies, classified
according to their diagnosis.
Characteristics CRC AA NAA NC
Proof of concept n (%) 11 (6.3) 67 (39.0) 38 (22.1) 56 (32.6)
Age (mean, range) 61 (50–69) 61 (50–69) 60 (50–69) 59 (49–69)
Sex, female (%) 6 (54.5) 19 (28.3) 15 (39.5) 37 (66.1)
Clinical validation n (%) 19 (5.8) 124 (37.9) 85 (26.0) 99 (30.3)
Age (mean, range) 61 (54–69) 61 (50–73) 61 (50–70) 58 (49–69)
Sex, female (%) 6 (31.6) 52 (41.9) 42 (49.4) 53 (53.5)
CRC, colorectal cancer; AA, advanced adenoma; NAA, nonadvanced adenoma; NC, normal colonoscopy.
https://doi.org/10.1371/journal.pone.0243158.t001
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All subjects underwent colonoscopy to determine their colorectal status. According to
endoscopic examination and pathology results, diagnosis was classified into four groups: nor-
mal colonoscopy (colonoscopy with no findings or with sigma and/or rectum hyperplastic pol-
yps <10 mm), nonadvanced adenomas (NAAs; tubular adenomas <10 mm with low-grade
dysplasia), AAs (adenomas�10 mm or with villous component or high-grade dysplasia, and
pTis adenocarcinoma), and invasive CRC. Serrated lesions were classified in the NAA (lesions
<10 mm without dysplasia) or AA (lesions�10 mm or with dysplasia) groups. Advanced neo-
plasms were defined as AA or invasive CRC. Individuals were also asked to answer a question-
naire to record clinical and epidemiologic data.
This proof-of-concept allowed us to develop an algorithm that discriminates between
healthy subjects and those with AN. It was validated on an independent cohort consisting of
359 consecutive FIT-positive participants in the national CRC screening program (Table 1).
Clinical validation was designed as a cross-sectional, multicenter study; the protocol (clinical
investigation code: GG-RAIDCRC-1002) was approved by the Clinical Research Ethics Com-
mittee of Hospital Universitari Dr. Josep Trueta-IAS and Hospital Universitari de Bellvitge.
Written informed consent was obtained from all study participants. According to the endo-
scopic findings, subjects were classified into the four groups previously mentioned. From the
359 recruited subjects, 32 had to be excluded from the study for different reasons: the subject
did not collect the stool sample, the sample was incorrectly conserved, there was no colono-
scopic diagnosis, and the sample condition was poor. Finally, 327 samples were used for the
clinical validation of RAID-CRC Screen.
Fecal sample collection
Participants were asked to collect a stool sample from one bowel movement in a sterile con-
tainer before colonoscopy and prior to bowel cleansing. Samples were immediately frozen
after deposition. Then, subjects brought samples to the hospital, where they were kept frozen
at -20˚C for short-term storage and stored at -80˚C upon arrival at the GoodGut S.L. facilities
in Girona (Spain).
DNA extraction from stool samples
Genomic DNA was extracted from frozen fecal samples after homogenization using the
NucleoSpin1 Soil Kit (Macherey-Nagel GMbH & Co., Duren, Germany). The instructions of
the manufacturer were followed, and the DNA was finally eluted in a 100 μl final volume of SE
Elution Buffer and stored at -20˚C until use. The DNA concentration was determined with
Qubit fluorometric quantification (Thermo Fisher Scientific, Massachusetts, USA).
qPCR assay for CRC biomarkers
The specific bacterial sequences targeted were classified into five different groups according to
their characteristics: Eubacteria (EUB) as the total bacterial load [22]; B10 (best BLAST match
F. prausnitzii), B46 (best BLAST match S. variabile), B48 (best BLAST match Ruminococcus,
Roseburia, Coprococcus), FPRA [23], and Roseburia intestinalis (RSBI) as butyrate-producing
bacterial biomarkers; GMLL, PTST, and BCTF as opportunistic pathogens usually found in
the oral cavity or in the bowel of mammals; Bacteroides thetaiotaomicron (BCTT) as a sacchar-
olytic species; and Escherichia coli (ECO) as a proinflammatory species [24].
Quantification of CRC-specific biomarkers was performed by preparing specific reactions
for each biomarker using SYBR Green Master Mix (Promega, Madison, USA) or Probe Master
Mix (Promega, Madison, USA). The sequences of the forward and reverse primers and probes
(when applied) are described in S1 Table. Each reaction consisted of 10 μl containing 1×
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GoTaq qPCR Master Mix, between 150 nM and 300 nM of each primer and/or probe, and up
to 10 ng of genomic DNA template. The species-specific primers were purchased from Macro-
gen (Macrogen, Seoul, South Korea). All qPCR was run on an AriaMx Real-time PCR System
(Agilent Technologies, Santa Clara, USA). Thermal profiles were different according to the
biomarker analyzed (S2 Table). A melting curve step was added to the end of each qPCR to
verify the presence of the expected amplicon size as well as to control primer dimer formation.
Data were collected and analyzed with Aria Software version 1.5 (Agilent Technologies, Santa
Clara, USA). All samples were amplified in duplicate and were considered valid when the dif-
ference between threshold cycles (Ct) was less than 0.6. A no-template control reaction and a
standard curve (sequential dilutions from 107 to 103 genomic units/μL) were included in each
PCR run to check qPCR efficiency.
In terms of qualitative analysis, the absence of a biomarker was considered if the obtained
Ct value was not within its dynamic range, which is the interval of relative abundance in which
a given bacterial marker can exist.
Statistical analysis
Data normality was assessed through the Kolmogorov-Smirnov test. The nonparametric Krus-
kal-Wallis test was used to test differences in variables with more than two categories. Pairwise
comparisons of subcategories of these variables were analyzed using a Mann-Whitney test. All
comparisons using bacterial markers were performed between the relative abundances, which
were normalized by the dynamic range of each bacterial marker.
Receiver operating characteristic (ROC) curve analysis was applied to determine the useful-
ness of each biomarker to distinguish among different colorectal neoplasia statuses. The accu-
racy of discrimination of each bacterial marker was measured by the area under the ROC
curve. Since RAID-CRC Screen is a qualitative approach, the performance of the designed algo-
rithm was calculated using likelihood ratios.
In the proof-of-concept study, machine learning was used to determine which combination
of bacterial markers was capable of distinguishing subjects with AN from those with normal
colonoscopy or NAA. The specific methodology consisted of an initial training iteration with
70% of 100 random partitions of the dataset and further validation with 30% of the remaining
predictive models generated using 4 different machine learning algorithms (neural network,
logistic regression, gradient boosting tree, and random forest). RAID-CRC Screen was eventu-
ally designed using a combination of six of the bacterial markers.
The clinical validation was performed in 359 subjects. Sample size was calculated using the
online platform GRANMO v7.12, estimating the population by proportions, with a 95% confi-
dence interval, an accuracy of +/- 5%, estimating a population percentage that is expected to
be approximately 30%, with 10% repositions foreseen.
The sensitivity, specificity, PPV, negative predictive value, and accuracy of the designed
algorithm were calculated using Epidat 3.1 software (SERGAS, Xunta de Galicia, Spain).
All remaining statistical analyses were performed using the SPSS 23.0 statistical package
(IBM, NYC, USA). Significance levels were established for p-values� 0.05.
Results
Proof-of-concept study
Fecal bacterial markers in neoplasia progression. In the proof-of-concept study, stool
samples were used to evaluate the relative abundance of each bacterial marker according to
each diagnosis (Fig 1). Regardless of the colonoscopy result, the most prevalent bacterial spe-
cies were butyrate producers (B10, B46, B48, FPRA, and RSBI), with relative abundance values
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of 16.7%, 14.2%, 16.1%, 14.1%, and 10.8%, respectively. Compared to healthy individuals, sub-
jects with either NAA or AA showed a higher absolute abundance of B10, B46 and FPRA
(p = 0.018, p = 0.004, and p = 0.023, respectively). PTST and BCTF absolute abundance was
significantly higher in the CRC population than in individuals with normal colonoscopy
(p = 0.002 and p = 0.017, respectively). Although there were no significant differences, a ten-
dency could be observed in GMLL, as it showed a higher absolute abundance in CRC patients
(p = 0.073); similarly, PTST and RSBI absolute abundances were higher in the presence of
either NAA or AA (p = 0.056 and 0.060, respectively). Regarding ECO, no significant differ-
ences were observed among the studied groups.
On the one hand, higher absolute abundances of opportunistic pathogens (GMLL, PTST,
and BCTF) were observed in CRC patients with respect to healthy subjects (p = 0.073,
p = 0.002, and p = 0.017, respectively). In terms of prevalence, these bacterial markers were
found more often in patients with CRC (GMLL, 75.0%; PTST, 50.0%; and BCTF, 66.6%) than
in healthy subjects (GMLL, 40.8%; PTST, 11.1%; and BCTF, 31.3%). On the other hand, when
subjects with normal colonoscopy were compared to patients with AN, three butyrate-produc-
ing bacteria (B10, B46, and FPRA) showed significant differences in their absolute abundance
(p = 0.035, p = 0.030, and p = 0.042, respectively).
RAID-CRC Screen algorithm development. The development of the RAID-CRC Screen
algorithm was aimed at reducing false-positive results for AN among FIT-positive subjects
while maintaining 100% sensitivity for CRC. FPRA, B46, and B10 were the only bacterial
markers that showed significant differences between subjects with normal colonoscopy or
Fig 1. Relative abundance of the analyzed bacterial markers in subjects with normal colonoscopy (NC), nonadvanced adenoma (NAA), advanced adenoma (AA),
and colorectal cancer (CRC). F. prausnitzii (FPRA), G. morbillorum (GMLL), P. stomatis (PTST), B. fragilis (BCTF), B. thetaiotaomicron (BCTT), R. intestinalis (RSBI)
and E. coli (ECO)).
https://doi.org/10.1371/journal.pone.0243158.g001
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NAA and those with AN within the FIT-positive population; however, they did not provide
the desired sensitivity values. An algorithm based on the combination of FPRA and B46 with
three other bacterial species (B48, GMLL, and BCTF) and the total bacterial load exhibited a
sensitivity of 94.8%, a specificity of 26.1%, a PPV of 50.0%, and a negative predictive value of
86.0% for AN (Table 2). More specifically, RAID-CRC Screen consists of 5 bacterial ratios:
FPRA/EUB, B46/EUB, B48/EUB, GMLL/EUB, and BCTF/EUB applied to the FIT-positive
population. While FIT 20 μg/g led to 94 false-positive results for AN detection, RAID-CRC
Screen reduced this value to 62, implying a reduction of 34% in the false-positive rate. Notably,
developers focused on sensitivity for AN, which reached 94.8%.
Clinical validation study
When RAID-CRC Screen was scaled up to the 327 FIT-positive individuals of the validation
cohort, sensitivities of 94.7%, 82.3%, and 83.9% were obtained for the detection of CRC, AA
and AN, respectively (Table 3). Specificities were 16.3% among participants with NAA or nor-
mal colonoscopy and 18.2% among those with negative results on colonoscopy (Table 3). In
this validation study, the algorithm detected 30 true negative subjects but generated 23 false
negatives from the 327 FIT-positive individuals, 22 of them with AA and 1 with CRC. More
importantly, while using FIT 20 μg/g, there were 184 false-positive results for AN, and
RAID-CRC Screen reduced this figure to 154, which implies a reduction of 16.3% in the false-
positive rate.
Discussion
Early detection of CRC is crucial for reducing its incidence and mortality. The European
Union recommends population-based, organized screening for CRC using evidence-based
methods with quality assurance of the entire screening process [25]. The best CRC screening
strategy has not yet been defined, but the most widely used strategy in Western countries is
FIT, which shows 79.0% sensitivity and 99.0% negative predictive value for CRC detection
[12]. The most common limitation of FIT-based CRC screening programs is false-positive
Table 2. Diagnostic performance of RAID-CRC Screen in the proof-of-concept study (n = 172).
Most advanced finding Groups used for calculating specificity Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Colorectal cancer (n = 11) NAA+NC 100.0 28.0 13.0 100.0
Advanced adenoma (n = 67) NAA+NC 94.0 26.0 49.0 88.0
Advanced neoplasia (n = 78) NAA+NC 94.8 26.1 50.0 86.0
NC, normal colonoscopy; NAA, nonadvanced adenoma; PPV, positive predictive value; NPV, negative predictive value.
https://doi.org/10.1371/journal.pone.0243158.t002
Table 3. Diagnostic performance of RAID-CRC Screen in the validation study (n = 327).
Most advanced finding Groups used for calculating specificity Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Colorectal cancer (n = 19) NC+NAA 94.7 16.3 10.5 96.8
NC 94.7 18.2 18.2 94.7
Advanced adenoma (n = 124) NC+NAA 82.3 16.3 49.8 57.7
NC 82.3 18.2 55.7 45.0
Advanced neoplasia (n = 143) NC+NAA 83.9 16.3 43.8 56.6
NC 83.9 18.2 59.7 43.9
NC, normal colonoscopy; NAA, nonadvanced adenoma; PPV, positive predictive value; NPV, negative predictive value.
https://doi.org/10.1371/journal.pone.0243158.t003
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results [26], as they lead to patient concerns, additional costs [27], and adverse events associ-
ated with unnecessary colonoscopies. In this study, we have defined and clinically validated a
fecal bacterial signature that complements FIT by reducing its associated false-positive rate
among FIT-positive participants.
Different bacterial markers associated with CRC have been analyzed in a proof-of-concept
study in subjects with colorectal neoplastic lesions at different stages: normal colonoscopy,
NAA, AA and CRC. Our qPCR results indicate the existence of microbial dysbiosis in patients
with CRC. The analyzed bacterial markers were classified according to their gut health-related
phenotypes: butyrate-producing bacteria (B10, B46, B48, FPRA, RSBI), saccharolytic bacteria
(BCTT), opportunistic pathogens (GMLL, PTST, BCTF), and proinflammatory bacteria
(ECO) (Fig 2). The relative abundance of these microbiological groups differed significantly
when healthy subjects were compared to CRC patients. Specifically, compared to subjects with
normal colonoscopy, those with CRC exhibited a decreased abundance of butyrate-producing
bacteria, which were replaced by pathogenic species. Unlike other studies, ECO did not display
variations across different diagnostics [28]. Although BCTF has been considered a carcinogen-
esis driver, it was found in higher abundances solely in CRC [29,30].
The combination of these data with the FIT value was used to develop a screening method
capable of discriminating between healthy subjects and patients with AN. The correct classifi-
cation of subjects with CRC was prioritized; thus, a 100% sensitivity was sought. The algorithm
was applied only to subjects with an FIT20 positive result (cut-off 20 μg hemoglobin/g feces)
and was intended to maximize the reduction in FIT20 false-positive results while maintaining
a high sensitivity for AN.
Fig 2. Relative abundance of the analyzed bacterial markers in subjects with normal colonoscopy (NC), nonadvanced adenoma (NAA), advanced adenoma (AA),
and colorectal cancer (CRC). Butyrate-producing species (B10, B46, B48, FPRA, and RSBI); opportunistic pathogens (GMLL, PTST, BCTF); saccharolytic bacteria
(BCTT); proinflammatory (ECO).
https://doi.org/10.1371/journal.pone.0243158.g002
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The defined microbiological signature combines five bacterial marker abundance ratios
(FPRA/EUB, GMLL/EUB, B46/EUB, BCTF/EUB, B48/EUB). Our results showed that high
FPRA/EUB, GMLL/EUB, and BCTF/EUB bacterial ratios correlated with the presence of AN.
In contrast, low B46/EUB and B48/EUB bacterial ratios correlated with healthy individuals
and AN, respectively. Notably, the use of the total bacterial load for data normalization is criti-
cal for controlling variables associated with qPCR, thus differentiating true biological changes
from experimentally induced variation [31].
Clinical validation of RAID-CRC Screen confirmed high sensitivity (94.7%) and negative
predictive values (96.8%) for CRC detection among FIT-positive individuals, respectively.
Concerning the detection of AA, promising results were also obtained with a sensitivity of
82.3%. Altogether, RAID-CRC Screen reached a sensitivity and specificity of 83.9% and 18.2%,
respectively, for the detection of AN. More importantly, the use of this new noninvasive tool
achieved a reduction in unnecessary colonoscopies of up to 20% among subjects who tested
positive for FIT. In addition, cancer screening programs seek methods with high negative pre-
dictive values since all affected individuals should be detected.
Although the two-step approach (FIT-positive result plus colonoscopy) is an efficient CRC
screening strategy in an average-risk population [32,33], the use of bacterial signatures after
testing positive in FIT may increase cost-effectiveness, as the number of unnecessary colonos-
copies would be further reduced. Moreover, the use of fecal bacterial signatures might facilitate
the implementation of CRC screening programs in resource-deprived regions, where colonos-
copy availability is limited. The geographical origin of sample donors has been a matter of con-
troversy that could impact the reproducibility of fecal bacterial signatures. This issue has been
recently assessed by some research groups by performing meta-analyses with cohorts from dif-
ferent origins (USA, Germany, France, Italy, China, Canada, and Austria), and were able to
identify reproducible microbiome markers in patients with CRC [19,34].
Since RAID-CRC Screen would be implemented in CRC screening organized programs,
sample collection, conservation, and transport must be adapted to the existing circuits. There-
fore, we have set up the detection of RAID-CRC Screen by qPCR from a unique sample taken
with the FIT tube collector [20]. Thus, the availability of this screening test is linked to that of
the general screening programs based on FIT. As for the cost, it will be slightly over the cost of
FIT, considering further processing, but taking into account the reduction of colonoscopies it
still will be more cost-effective than the current system.
Based on our results, we propose a three-step CRC screening strategy in which the bacterial
signature (RAID-CRC Screen) is applied to FIT-positive individuals for a better selection of
those who should undergo colonoscopy. This approach was associated with a significant
reduction in false-positive FIT results among participants in a population-based, organized
CRC screening program. Therefore, RAID-CRC Screen is being postulated as a new noninva-
sive tool for CRC screening, adding specificity and PPV to FIT while maintaining high sensi-
tivity for AN.
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S1 Table. Forward and reverse primers, and probe sequences used in this work. EUB,
Eubacteria; GMLL, G. morbillorum; PTST, P. stomatis; BCTF, B. fragilis; BCTT, B. thetaiotao-
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primer; PR, probe. FPRA probe was 5’-labelled with FAM (6-carboxyfluorescin) as the
reporter dye and TAMRA was used as quencher dye at the 3’-end.
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E. coli; NA, nonapplicable.
(DOCX)
Acknowledgments
We thank Ms. Alba Pla, Ms. Alba Costa, Ms. Roser Coll, Ms. Jessica Fernandez, Mr. Guillem
Clos (Gastroenterology Department, Institut d’Assistència Sanitària (IAS), Salt); Ms. Dolors
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Serra-Pagès, Xavier Aldeguer, L. Jesús Garcia-Gil.
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Writing – review & editing: Marta Malagón, Sara Ramió-Pujol, Marta Serrano, Joan Amoedo,
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cáncer colorrectal en la población general. Plan de Calidad para el SNS del MSC. Servicio de Evalua-
ción del Servicio Canario de Salud. Informes de Evaluación de Tecnologı́as Sanitarias: SESCS N˚
2006/23. 2010.
8. Groenen PJTA, Van Krieken JH, Murray S, Rouleau E, Garborg, HolmeØ, et al. Current status of
screening for colorectal cancer. Ann Oncol. 2013; 24: 1963–1972. https://doi.org/10.1093/annonc/
mdt157 PMID: 23619033
9. Stracci F, Zorzi M, Grazzini G, Efird JT. Colorectal cancer screening: tests, strategies, and perspec-
tives. Front Public Heal. 2014; 2: 1–9. https://doi.org/10.3389/fpubh.2014.00210 PMID: 25386553
10. Canal Salut. Gencat. Estadı́stiques del programa de detecció precoç del càncer de còlon i recte. [cited
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